CLINICAL TRIALS PROFILE FOR VENLAFAXINE HYDROCHLORIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for venlafaxine hydrochloride
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Dosage | NCT05875610 ↗ | Preventive Approach Using Venlafaxine | Recruiting | Mit Ghamr Oncology Center | Phase 4 | 2023-05-01 | Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for venlafaxine hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00001483 ↗ | Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 1995-06-01 | This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania. |
NCT00018902 ↗ | Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) | Completed | National Institute of Mental Health (NIMH) | Phase 2/Phase 3 | 2001-01-01 | The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy. |
NCT00018902 ↗ | Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) | Completed | University of Pittsburgh | Phase 2/Phase 3 | 2001-01-01 | The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for venlafaxine hydrochloride
Condition Name
Clinical Trial Locations for venlafaxine hydrochloride
Trials by Country
Clinical Trial Progress for venlafaxine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for venlafaxine hydrochloride
Sponsor Name